XML 22 R10.htm IDEA: XBRL DOCUMENT v3.25.2
REVENUES
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
Disaggregation of Revenues
The following table summarizes our Total revenues:
Three Months Ended June 30, 2025Three Months Ended June 30, 2024
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$2,799 $429 $302 $3,530 $2,585 $370 $277 $3,232 
Descovy601 24 28 653 434 25 26 485 
Genvoya322 40 16 377 372 45 23 440 
Odefsey221 66 11 298 233 72 10 315 
Symtuza - Revenue share(1)
88 33 3 124 131 34 3 168 
Other HIV(2)
65 33 9 107 65 25 15 105 
Total HIV4,096 624 368 5,088 3,821 571 353 4,745 
Liver Disease
Sofosbuvir/Velpatasvir(3)
184 81 76 342 267 84 126 476 
Vemlidy122 13 117 252 117 11 115 243 
Other Liver Disease(4)
106 76 19 201 47 47 19 113 
Total Liver Disease413 170 211 795 431 142 259 832 
Veklury51 19 50 121 76 53 85 214 
Oncology
Cell Therapy
Tecartus41 41 9 92 63 37 7 107 
Yescarta162 154 77 393 186 169 58 414 
Total Cell Therapy203 196 86 485 250 206 66 521 
Trodelvy224 96 44 364 224 69 26 320 
Total Oncology427 291 131 849 474 275 92 841 
Other
AmBisome7 65 56 129 17 69 65 151 
Other(5)
44 8 21 73 98 8 24 130 
Total Other52 73 77 202 115 77 88 280 
Total product sales5,038 1,178 838 7,054 4,916 1,118 878 6,912 
Royalty, contract and other revenues13 10 4 27 25 15 1 41 
Total revenues$5,051 $1,189 $842 $7,082 $4,941 $1,133 $879 $6,954 
Six Months Ended June 30, 2025Six Months Ended June 30, 2024
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$5,272 $804 $603 $6,679 $4,900 $735 $542 $6,177 
Descovy1,139 45 55 1,239 805 51 55 911 
Genvoya627 79 35 741 704 95 44 843 
Odefsey436 123 20 579 457 148 21 626 
Symtuza - Revenue share(1)
170 62 6 238 236 67 6 309 
Other HIV(2)
115 63 19 198 125 70 27 222 
Total HIV7,760 1,177 738 9,675 7,226 1,167 695 9,088 
Liver Disease
Sofosbuvir/Velpatasvir(3)
351 161 175 687 515 163 203 881 
Vemlidy222 24 257 504 212 22 233 467 
Other Liver Disease(4)
175 152 35 362 89 94 38 221 
Total Liver Disease748 338 467 1,553 816 279 474 1,569 
Veklury250 41 132 423 391 123 255 769 
Oncology
Cell Therapy
Tecartus82 72 17 171 118 73 16 207 
Yescarta321 304 154 779 357 327 110 794 
Total Cell Therapy403 376 171 949 475 400 126 1,001 
Trodelvy405 171 81 657 429 137 62 628 
Total Oncology808 547 252 1,606 904 537 188 1,629 
Other
AmBisome13 132 123 268 31 139 124 294 
Other(5)
91 16 35 143 156 18 36 209 
Total Other104 149 158 410 188 156 160 504 
Total product sales9,669 2,251 1,747 13,668 9,525 2,262 1,772 13,559 
Royalty, contract and other revenues49 21 10 81 49 30 2 81 
Total revenues$9,719 $2,273 $1,757 $13,749 $9,574 $2,292 $1,774 $13,640 
_______________________________
(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”).
(2)    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada, Tybost and Yeztugo.
(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi.
(5)    Includes Cayston, Jyseleca, Letairis and Zydelig.
Revenues Recognized from Performance Obligations Satisfied in Prior Years
The following table summarizes revenues recognized from performance obligations satisfied in prior years:
Three Months EndedSix Months Ended
June 30,June 30,
(in millions)2025202420252024
Revenue share with Janssen Ireland and royalties for licenses of intellectual property$153 $202 $310 $372 
Changes in estimates$126 $82 $340 $242 
Contract Balances
The following table summarizes our contract balances:
(in millions)June 30, 2025December 31, 2024
Contract assets$305 $277 
Contract liabilities(1)
$58 $58 
_______________________________
(1)    Future revenues recognized from contract liabilities are not expected to be material in any one year.